close
Add to watchlist
Novogen Depository Receipt (NVGN) Healthcare, Biotechnology & Drugs
Novogen Limited and its subsidiaries engage in the research and development of pharmaceutical products, and marketing of consumer healthcare products. Its consumer healthcare products comprise Promensil, a range of natural products specifically for women's health; Trinovin, a natural product specifically for men's midlife health; and Vinalac, a probiotic formula to help prevent childhood allergies, such as eczema in children at risk of an allergy. The company is developing various pharmaceutical products, including Phenoxodiol, a phase III investigational drug for late stage, chemoresistant ovarian cancer and prostate, and cervical cancers; Triphendiol, a phase I signal transduction inhibitor for the treatment of cholangiocarcinoma or bile duct cancer, and stage IIB through stage IV malignant melanoma; NV-128, a pre-clinical stage cancer compound to promote cancer cell death in multi–drug resistant ovarian cancer cells by targeting the AKT-mTOR pathway; anti-inflammatory product NV-52, a phase Ib drug for the treatment of inflammatory bowel disease; and FAIMs, flavonoid anti-inflammatory molecules to avoid cardiovascular, gastrointestinal, and renal side effects associated with anti-inflammatory drugs. It is also developing NV-27, a phase I drug to reduce restenosis or reblocking of arteries after surgery to clear blockages, commonly involving insertion of arterial stents; and GLYC-101, a phase IIa product for the treatment of burn wounds. Novogen Limited offers its products in Australia, North America, and Europe. The company was founded in 1994 and is headquartered in North Ryde, Australia.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 2.43 |
| Volume | 2375 |
| Volume Avg | 5156 |
| 52 Week High | 74.25 |
| 52 Week Low | 2.03 |
| PE | 3.79 |
| PE (group average) | 39 |
| EPS Year | 0.63 |
| EPS change Q/Q | 100% |
| EPS change Q/Q Yr ago | -33.33% |
| EPS change Q/Q next Q est | 100% |
| EPS change Y/Y | -54.55% |
| REV change Q/Q | -100% |
| REV change Q/Q Yr ago | 21.82% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |